Corona Remedies Q1FY27 Revenue Up 21.9% to ₹422.4 Cr

Corona Remedies Ltd reported a strong start to FY27 with unaudited financial results for Q1FY27. Revenue from operations grew by 21.9% year-on-year to ₹422.4 Cr, driven by robust brand building and operational excellence. Profit After Tax (PAT) increased by 30.1% year-on-year to ₹60.1 Cr, with PAT margins improving by 90 basis points to 14.2%. The company continues to outperform the Indian Pharmaceutical Market (IPM) and has moved up to the 26th rank. Key business highlights include the inauguration of an EU-GMP approved Female Hormone Manufacturing Facility and the integration of the acquired brand Wokadine. The company remains focused on core therapies like Women's Healthcare and Cardio-diabetes.